Executive summary
US Patent 12,311,027 is directed to a liquid pharmaceutical composition for CNS indications that combines “Compound 1” with a specific surfactant/emulsifier system: sorbitan laurate (b) plus polysorbate 20 (c) in a defined weight ratio (~5:2 by weight) and with a stability constraint requiring <10 ppm of a Compound 1 hydrolysis product. The claim set then pivots to method-of-use coverage for major psychiatric disorders (schizophrenia, bipolar disorder, anxiety, depression, autism-related irritability, and acute mania) via administration of the claimed composition. The protection scope is therefore anchored to (i) the exact excipient pair and ratio, (ii) surfactant concentration ranges, (iii) a quantified degradation impurity limit, and (iv) the CNS therapeutic indications.
What does US Patent 12,311,027 claim protect and what is the independent claim scope?
Short answer: The patent protects a formulation defined by Compound 1 + sorbitan laurate + polysorbate 20 + aqueous vehicle, plus a stability/spec impurity limit (<10 ppm hydrolysis product) and a surfactant ratio of about 5:2 by weight. It also protects methods of treating psychiatric disorders by administering that formulation.
Claim 1: core formulation gatekeepers
Claim 1 recites four structural elements and two gating constraints.
Element set
- (a) Compound 1
- (b) sorbitan laurate
- (c) polysorbate 20
- (d) aqueous vehicle
Key quantitative constraints
- Impurity/degradation limit: composition has <10 ppm of the hydrolysis product of Compound 1
- Surfactant ratio constraint: (b):(c) ≈ 5:2 by weight
Functional constraint that drives infringement analysis
- The <10 ppm hydrolysis product condition makes the claim behave like a stability and analytical-spec claim. In practice, infringement turns on whether the accused formulation (as manufactured and/or as administered under relevant storage/use conditions) meets the impurity limit and produces/contains the specified degradation level.
Dependent claims 3–5: composition ranges and specific embodiments
Your text provides quantitative dependent claims that tighten ranges beyond claim 1.
Claim 3
- Compound 1: 24–30 wt%
- Sorbitan laurate: 0.3–0.4 wt%
- Polysorbate 20: ~0.1–0.3 wt%
- Aqueous vehicle
Claim 4 (specific point)
- Compound 1: ~26.6 wt%
- Sorbitan laurate: ~0.37 wt%
- Polysorbate 20: ~0.15 wt%
- Aqueous vehicle
Claim 5
- Compound 1: 15–35 wt%
- Sorbitan laurate: ~0.2–1 wt%
- Polysorbate 20: ~0.1–0.3 wt%
- Aqueous vehicle
How these ranges interact with the 5:2 ratio
Across the listed preferred embodiments, the sorbitan laurate and polysorbate 20 ranges are consistent with a ratio order-of-magnitude that supports the claim 1 requirement. The ratio constraint in claim 1 is likely the hardest to design around, because moving the ratio to non-infringing territory risks falling outside every dependent claim’s practical window.
Dependent claims 2, 13, 14, 15: hydrolysis product definition
Claims 2, 13, 14, and 15 appear to define the identity of the “hydrolysis product of Compound 1.” Your excerpt does not show the actual chemical definition(s) that those claims recite.
Practical impact
- If the patent defines a specific hydrolysis product structure (or a particular analytical marker), infringement can be attacked by showing the impurity is a different species or falls below a different reporting standard.
- If, instead, it defines the hydrolysis product broadly (class-based or analytical method based), infringement is less susceptible to “species switching.”
How broad is the formulation protection under US 12,311,027 given the excipient ratio and <10 ppm hydrolysis limit?
Short answer: The claim breadth is constrained by two high-specificity anchors: the surfactant pair with an approximate 5:2 wt ratio and the sub-10-ppm hydrolysis impurity limit. Those two features narrow the space of design-arounds more than typical excipient “presence” claims.
Breadth drivers
-
Excipient pairing is mandatory
The formulation must include both sorbitan laurate and polysorbate 20, not merely “a surfactant system.”
-
Ratio is anchored
“Approximately 5 to 2” by weight introduces a tolerance band. The breadth depends on how “approximately” is interpreted in claim construction, but even with tolerance, it remains a measurable design variable.
-
Impurity limit is quantified
“Less than 10 ppm” is a bright-line numerical threshold. Even if a competitor can match the excipient ratio, it must also meet the analytical requirement.
-
Concentration ranges are relatively wide in claim 5
Claim 5 covers compound 1 from 15–35 wt%, sorbitan laurate 0.2–1 wt%, and polysorbate 20 ~0.1–0.3 wt%. That range breadth may matter for reformulation freedom only if the ratio and impurity limit can still be met.
Where breadth stops
- If a competitor changes the excipient system (e.g., swaps polysorbate 20 for polysorbate 80, or replaces sorbitan laurate with another sorbitan ester), it risks bypassing claim 1 entirely.
- If a competitor keeps the same two excipients but alters the ratio materially, it risks leaving “approximately 5 to 2” territory.
- If a competitor’s formulation does not suppress the Compound 1 hydrolysis product to <10 ppm, it risks non-infringement only if a court construes the impurity measurement strictly and the competitor can prove compliance.
Which method-of-use claims are covered, and what indications does US 12,311,027 reach?
Short answer: The patent claims administration of the claimed formulation for schizophrenia, bipolar disorder, anxiety, depression, autism-related irritability, and acute mania.
Method-of-use claims in your excerpt
- Claim 6: treating schizophrenia with claim 1 composition
- Claim 7: treating schizophrenia with claim 3 composition
- Claim 8: treating bipolar disorder with claim 1 composition
- Claim 9: treating anxiety with claim 1 composition
- Claim 10: treating depression with claim 1 composition
- Claim 11: treating autism-related irritability with claim 1 composition
- Claim 12: treating acute mania with claim 3 composition
Indication scope and competitive implications
- The claim set spans both DSM-style diagnostic labels and a pediatric behavioral subset (autism-related irritability).
- This breadth increases litigation leverage because a challenger cannot easily argue “the patent only covers schizophrenia” if the same formulation is used for adjacent indications.
What formulations are protected: liquid aqueous compositions with sorbitan laurate and polysorbate 20?
Short answer: The formulation is explicitly an aqueous vehicle with mandatory Compound 1 + sorbitan laurate + polysorbate 20.
Dosage form inference
Your claims do not specify oral solution, suspension, or injectable route, but the “aqueous vehicle” language plus classic surfactant pairing is consistent with liquid dosage forms.
Formulation design constraints
- The excipient pair is functionally linked to hydrolysis suppression.
- The formulation must meet <10 ppm hydrolysis product at relevant conditions defined by the patent’s examples/assay methods (not included in your excerpt). Those assay and test conditions drive enforceability and practical infringement testing.
How strong is the patent estate for this formulation and what matters for enforceability?
Short answer: Strength is driven by the specificity of (i) the excipient ratio and (ii) the numerical impurity cap, with enforceability hinging on the patent’s analytical definition of “hydrolysis product” and the testing conditions for “ppm.”
Key enforceability levers
- Claim construction of “approximately 5 to 2 by weight”
- A narrower tolerance band strengthens enforcement; a broader construction weakens it.
- Analytical definition of the “hydrolysis product”
- If the patent specifies a defined marker, method, or species, infringement disputes become test-method dependent.
- Assay context
- If the patent measures impurity after a stability study, challengers can litigate whether the relevant timepoint and storage profile match the patent’s described conditions.
What generic entry risks exist for products that use different surfactants or different ratios?
Short answer: The highest risk for generics is copying the surfactant system closely enough to hit the ratio constraint and the <10 ppm impurity constraint. The biggest design-around lever is replacing or moving away from the sorbitan laurate + polysorbate 20 system, but that can increase degradation risk depending on how Compound 1 behaves.
Design-around scenarios (claim-targeted)
- Swap polysorbate 20 for another surfactant
Likely avoids claim 1 because (c) becomes different.
- Swap sorbitan laurate for another sorbitan ester
Likely avoids claim 1 because (b) becomes different.
- Keep both excipients but alter their ratio beyond “approximately 5:2”
May avoid claim 1. Success depends on the construed tolerance.
- Keep ratio and excipients but relax impurity control
If hydrolysis product rises above 10 ppm, it can avoid claim 1, but only if the impurity is measured and reported the same way.
When do composition and method-of-use claims matter in Paragraph IV or section viii carve-outs?
Short answer: For any regulatory pathway using an ANDA-style approach, this type of formulation patent is typically asserted against generics at the composition level because the claim is a direct pharmaceutical composition with defined excipients and impurity threshold. Method-of-use claims can broaden litigation even if a generic targets an indication other than schizophrenia, depending on labeling.
Carve-out sensitivity
- If a generic’s proposed labeling omits some indications, method-of-use claims can still be asserted if the label includes covered uses.
- Composition-only products with different indication labeling can still face composition patent assertions.
(Your excerpt does not include Orange Book status, listed patents, or FDA submission history, so no timeline can be stated here.)
How does the claim architecture compare with typical psychotropic formulation patents?
Short answer: US 12,311,027 is more “formulation-specified” than broad “a pharmaceutically acceptable vehicle” patents because it includes both surfactant ratio and a specific impurity cap tied to hydrolysis.
Comparison dimensions
- Many formulation patents protect generic excipient inclusion; here, excipient inclusion is paired with quantified performance (impurity <10 ppm).
- Many method-of-use patents cover a single indication; this one covers multiple psychiatric disorders across claims 6–12.
Geographic coverage: what jurisdictions does US 12,311,027 likely map to?
Short answer: The claims you provided are US claims. The excerpt does not identify foreign counterparts (e.g., EP, WO, JP, CA), so only US scope can be stated from your text.
Key Takeaways
- US 12,311,027 protects an aqueous composition comprising Compound 1 plus sorbitan laurate and polysorbate 20 in an approximate 5:2 wt ratio and containing <10 ppm of a Compound 1 hydrolysis product.
- Dependent claims narrow the formulation into specific concentration windows (notably ~26.6 wt% Compound 1 with ~0.37 wt% sorbitan laurate and ~0.15 wt% polysorbate 20).
- The patent extends beyond formulation to method-of-use coverage for schizophrenia, bipolar disorder, anxiety, depression, autism-related irritability, and acute mania, via administration of the claimed composition(s).
- The most litigation-relevant claim features are the ratio constraint and the numerical impurity limit, which can drive both infringement proof and design-around strategy.
FAQs
-
What single claim element is most effective for a design-around against US 12,311,027?
Changing the sorbitan laurate + polysorbate 20 system so the formulation falls outside the ~5:2 wt ratio and/or fails the <10 ppm hydrolysis product specification.
-
Do the method-of-use claims require the same composition as the independent composition claim?
The method claims in your excerpt are tethered to claim 1 or claim 3 compositions, so the accused product must match the corresponding formulation.
-
Can a product infringe if it uses sorbitan laurate and polysorbate 20 but has higher hydrolysis impurity?
If the formulation contains ≥10 ppm of the specified hydrolysis product (as measured under the patent’s analytical framework), it is outside claim 1’s impurity requirement.
-
How do dependent concentration ranges affect infringement risk?
They create additional, narrower embodiments (claims 3–5). A formulation meeting claim 1 could still infringe method claims if labeling uses covered indications, while a formulation outside claim 3 may avoid the specific claim 7/12 method tethering.
-
What evidence is typically most decisive in litigating a <10 ppm impurity claim?
Analytical chemistry results aligned to the patent’s definition of the hydrolysis product and the measurement conditions used in the patent record.
References
No external sources were cited because the prompt provided the claim text but not the patent document, bibliographic record, specification examples, prosecution history, or FDA/Orange Book listings for US Patent 12,311,027.
